OBJECTIVE: To explore the potential mechanism of WFY in treating HTS.
METHODS: Active components and corresponding targets were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. HTS-related genes were obtained from the GeneCards, DisGeNET, and National Center for Biotechnology Information. The function of targets was analyzed by performing Gene Ontology and Kyoto Encyclopaedia of Genes and Genome (KEGG) enrichment analysis. A protein + IBM-protein interaction (PPI) network was developed using STRING database and Cytoscape. To confirm the high affinity between compounds and targets, molecular docking was performed.
RESULTS: A total of 65 core genes, which were both related to compounds and HTS, were selected from multiple databases. PPI analysis showed that CKD2, ABCC1, MMP2, MMP9, glycogen synthase kinase 3 beta (GSK3B), PRARG, MMP3, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG) were the hub targets and MOL004941, MOL004935, MOL004866, MOL004993, and MOL004989 were the key compounds of WFY against HTS. The results of KEGG enrichment analysis demonstrated that the function of most genes were enriched in the PI3K-Akt pathway. Moreover, by performing molecular docking, we confirmed that GSK3B and 8-prenylated eriodictyol shared the highest affinity.
CONCLUSIONS: The current findings showed that the GSK3B and cyclin dependent kinase 2 were the potential targets and MOL004941, MOL004989, and MOL004993 were the main compounds of WFY in HTS treatment.
目的:探讨WFY治疗HTS的潜在机制。
方法:从中药系统药理学数据库和分析平台检索活性成分和相应的靶标。HTS相关基因从GeneCards获得,DisGeNet,和国家生物技术信息中心。通过进行基因本体论和京都基因和基因组百科全书(KEGG)富集分析来分析靶标的功能。使用STRING数据库和Cytoscape开发了蛋白质+IBM-蛋白质相互作用(PPI)网络。为了确认化合物和靶标之间的高亲和力,进行分子对接。
结果:共有65个核心基因,它们都与化合物和HTS有关,从多个数据库中选择。PPI分析显示CKD2、ABCC1、MMP2、MMP9、糖原合成酶激酶3β(GSK3B)、PRARG,MMP3和磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基γ(PIK3CG)是中心靶标,MOL004941,MOL004935,MOL004866,MOL004993和MOL004989是WFY抗HTS的关键化合物。KEGG富集分析结果表明,大多数基因的功能富集在PI3K-Akt途径中。此外,通过进行分子对接,我们证实GSK3B和8-异戊烯化的艾瑞替醇具有最高的亲和力.
结论:目前的研究结果表明,GSK3B和细胞周期蛋白依赖性激酶2是潜在的靶标,MOL004941,MOL004989和MOL004993是WFY在HTS治疗中的主要化合物。